That’s a dim view of IPIX post trial potential and also complete BS. Merck’s
Ridgeback etc others. Plenty of deals being done for therapeutics. Will ipix be one of them, or will they blame things like not having a government lobbyist! No excuses at this stage. None. Only competency and not relying on a strategy of “if they build it, they will come (to us).”
Let’s see results in trial and dealmaking
Ipix owes both to their shareholder base, and achieving results without the other would be a deep insult and more of the same and usher in years to come of no follow thru.
Time
To
Shine
Time
To
Put up or shut up
Let’s see what you got, in many facets—data and deals!
Rooting for ya!
Market Data 
Markets 
AI
